Search by Drug Name or NDC
NDC 55150-0356-01 Plerixafor 24 mg/1.2mL Details
Plerixafor 24 mg/1.2mL
Plerixafor is a SUBCUTANEOUS SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Eugia US LLC. The primary component is PLERIXAFOR.
MedlinePlus Drug Summary
Plerixafor injection is used along with a granulocyte-colony stimulating factor (G-CSF) medication such as filgrastim (Neupogen) or pegfilgrastim (Neulasta) to prepare the blood for an autologous stem cell transplant (procedure in which certain blood cells are removed from the body and then returned to the body after chemotherapy and/or radiation) in patients with non-Hodgkin's lymphoma (NHL; cancer that begins in a type of white blood cells that normally fights infection) or multiple myeloma (a type of cancer of the bone marrow). Plerixafor injection is in a class of medications called hematopoeitic stem cell mobilizers. It works by causing certain blood cells to move from the bone marrow to the blood so that they can be removed for transplant.
Related Packages: 55150-0356-01Last Updated: 04/21/2024
MedLinePlus Full Drug Details: Plerixafor Injection
Product Information
| NDC | 55150-0356 |
|---|---|
| Product ID | 55150-356_bd79333b-3bf1-4f64-85a4-ccee347b7f79 |
| Associated GPIs | |
| GCN Sequence Number | 064684 |
| GCN Sequence Number Description | plerixafor VIAL 24MG/1.2ML SUBCUT |
| HIC3 | N1G |
| HIC3 Description | CXCR4 CHEMOKINE RECEPTOR ANTAGONIST |
| GCN | 16124 |
| HICL Sequence Number | 036021 |
| HICL Sequence Number Description | PLERIXAFOR |
| Brand/Generic | Generic |
| Proprietary Name | Plerixafor |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Plerixafor |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | SOLUTION |
| Route | SUBCUTANEOUS |
| Active Ingredient Strength | 24 |
| Active Ingredient Units | mg/1.2mL |
| Substance Name | PLERIXAFOR |
| Labeler Name | Eugia US LLC |
| Pharmaceutical Class | Hematopoietic Stem Cell Mobilizer [EPC], Increased Hematopoietic Stem Cell Mobilization [PE] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA213672 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 55150-0356-01 (55150035601)
| NDC Package Code | 55150-356-01 |
|---|---|
| Billing NDC | 55150035601 |
| Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (55150-356-01) / 1.2 mL in 1 VIAL, SINGLE-DOSE |
| Marketing Start Date | 2023-07-24 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |